MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
You're hunched over the engine with your wrist painfully contorted, wishing you were Mr. Fantastic. You've finally removed broken spark plug number four and then the intrusive thought hits. "Should I ...
MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...
Abstract: The SPARC Toroidal Field Model Coil (TFMC) Program was a three-year effort between 2018 and 2021 that developed novel rare earth barium copper oxide (REBCO) superconductor technologies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback